Foghorn (FHTX) news
Recent news
Foghorn Therapeutics Inc.: Wedbush cuts to neutral from outperform; cuts target price to $2 from $10
Wedbush Securities has downgraded Foghorn Therapeutics Inc. (FHTX) to "Neutral" from "Outperform" and simultaneously reduced its price target to $2 from $10, citing recent developments and revised expectations for the biotechnology firm. This move follows similar downgrades from TD Cowen and BTIG,…
AInvest Wire · Oct 2, 2026Foghorn Therapeutics Inc.: H.C. Wainwright cuts target price to $5 from $13
H.C. Wainwright has further reduced its price target for Foghorn Therapeutics Inc. (FHTX) to $5 from $13, while maintaining a "Buy" rating . This adjustment follows the company’s decision to discontinue independent development of FHD-286 . Despite this setback, the firm remains supportive of…
AInvest Wire · Oct 2, 2026Foghorn Therapeutics Inc.: BTIG cuts to neutral from buy
BTIG has revised its recommendation for Foghorn Therapeutics Inc. (FHTX), downgrading the stock from "Buy" to "Neutral". This adjustment reflects a reassessment of the company's current market position and performance. FHTX, a development-stage biopharmaceutical firm, is focused on chromatin…
AInvest Wire · Oct 2, 2026Foghorn Therapeutics Inc.: Jefferies cuts target price to $5 from $12
Jefferies has revised its price target for Foghorn Therapeutics Inc. (FHTX), reducing it from $12 to $5, a significant 58.33% decrease. Despite this adjustment, the firm has maintained its "Buy" rating for the biotechnology company, signaling continued confidence in its long-term potential . The…
AInvest Wire · Oct 2, 2026Foghorn Therapeutics shares hit record low after co scraps cancer drug development with Eli Lilly, to cut 40% of workforce, last down 46%
Foghorn Therapeutics Inc. (FHTX) shares fell more than 3% on Monday, hitting intraday lows not seen in over 10 months, following the company’s announcement to discontinue experimental drug FHD-286 in combination with decitabine for treating relapsed and/or refractory acute myeloid leukemia (AML).…
AInvest Wire · Oct 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.